What Do Analysts Predict for ROIV?

This afternoon we watched Roivant Sciences rise 4.8% to a price of $10.85 per share. The mid-cap Pharmaceutical company is now trading -30.3% below its average target price of $15.56. Analysts have set target prices ranging from $11.0 to $23.0 per share for Roivant Sciences, and have given the stock an average rating of buy.

The stock has an average amount of shares sold short at 7.1%, and a short ratio of 5.83. Since 30.27% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. Finally, we also note that an average number of institutional investors are invested in the stock, with 67.9% of Roivant Sciences's shares being owned by this investor type.

Institutions Invested in Roivant Sciences

Date Reported Holder Percentage Shares Value
2023-09-30 QVT Financial LP 14% 112,541,536 $1,221,075,708
2023-09-30 Viking Global Investors, L.P. 9% 73,434,301 $796,762,193
2023-09-30 SB Investment Advisers (UK) LTD 9% 73,031,667 $792,393,614
2023-09-30 FMR, LLC 5% 38,910,625 $422,180,296
2023-09-30 Morgan Stanley 2% 19,311,631 $209,531,203
2023-09-30 Blackrock Inc. 2% 17,723,537 $192,300,383
2023-09-30 Wellington Management Group, LLP 2% 14,842,976 $161,046,295
2023-09-30 Patient Square Capital LP 2% 12,639,920 $137,143,136
2023-09-30 Baker Brothers Advisors, LLC 1% 11,877,171 $128,867,309
2023-09-30 T. Rowe Price Investment Management, Inc. 1% 10,649,397 $115,545,961

Besides an analyst consensus of strong upside potential, other market factors point to there being positive market sentiment on Roivant Sciences.

The above analysis is intended for educational purposes only and was performed on the basis of publicly available data. It is not to be construed as a recommendation to buy or sell any security. Any buy, sell, or other recommendations mentioned in the article are direct quotations of consensus recommendations from the analysts covering the stock, and do not represent the opinions of Market Inference or its writers. Past performance, accounting data, and inferences about market position and corporate valuation are not reliable indicators of future price movements. Market Inference does not provide financial advice. Investors should conduct their own review and analysis of any company of interest before making an investment decision.